Ventyx Biosciences (NASDAQ:VTYX) Raised to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen has upgraded Ventyx Biosciences (NASDAQ:VTYX) from a "sell" rating to a "hold" rating in a recent report.
• The stock has seen a remarkable increase of 19.1%, opening at $2.81 with a market cap of approximately $199.96 million.
• Ventyx Biosciences reported a loss of ($0.38) earnings per share for the last quarter, better than the estimated loss of ($0.45).

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday.

Ventyx Biosciences Trading Up 9.2%

Shares of NASDAQ:VTYX traded up $0.24 during midday trading on Friday, hitting $2.87. The stock had a trading volume of 495,277 shares, compared to its average volume of 1,404,225. The company has a market capitalization of $204.73 million, a PE ratio of -1.71 and a beta of 0.97. The stock has a 50 day moving average price of $2.57 and a two-hundred day moving average price of $1.83. Ventyx Biosciences has a 1 year low of $0.78 and a 1 year high of $3.39.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.07. As a group, equities analysts expect that Ventyx Biosciences will post -2.09 EPS for the current year.

Institutional Trading of Ventyx Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd boosted its holdings in Ventyx Biosciences by 230.1% during the second quarter. XTX Topco Ltd now owns 161,611 shares of the company's stock worth $346,000 after buying an additional 112,660 shares in the last quarter. Catalyst Funds Management Pty Ltd purchased a new stake in Ventyx Biosciences during the second quarter worth about $61,000. Bailard Inc. purchased a new stake in Ventyx Biosciences during the second quarter worth about $88,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Ventyx Biosciences by 8.4% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 945,206 shares of the company's stock worth $2,023,000 after buying an additional 73,601 shares in the last quarter. Finally, Prospera Financial Services Inc purchased a new stake in Ventyx Biosciences during the second quarter worth about $319,000. Hedge funds and other institutional investors own 97.88% of the company's stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.